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Figure 1.1: The normal kidney. l. renal cortex; 2. renal medulla; 3. renal artery; 
4. renal vein; 5. ureter; 6. renal capsule; 7. renal pelvis 
Source: http://www. nhpress. com/pkd!kidney!parts. html 
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Figure 1.2: The Structure of the Nephron. 
Source: http://www.nhpress.com/pkd/kidney/howwork.html 

Figure 1.3: The Processes of Cystogenesis. A normal kidney can become cystic 
because the cells grow too quickly (hyperplasia), because fluid is secreted into 
the space as opposed to absorbed across it, or because of abnormalities in the 
extracellular matrix ( ECM). Source: HDCN Highlights of the 9th Annual 
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Figure 1.5: The predicted structure of the PKD I and PKD2 proteins and their interaction forming the polycystin complex. 
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Figure 1.6: Schematic Representation of the "Two Hit" Model for Cystogenesis 
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Figure 2.1: Map of Australia. This figure shows the city of Perth where the 
Australian index patients were ascertained. 
Source: http://www.nationalgeographic.com/xpeditionslatlas/ 
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Figure 2.2: The Recruitment Process and ADPKD Status of Australian Index Cases and Relatives Participating in the ADPKD Research Project 
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Figure 2.3: Map of Bulgaria. This figure shows the two cities ( Pleven and Plovdiv) 




Figure 2.4: Map of Poland. This figure shows the city of Krakow where the Polish 
index patients were ascertained. 
Source: http://www.nationalgeographic.com/xpeditions/atlas/ 
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Figure 2.6: Markers in the PKD I Region on Chromosome 16p 13.3 Used in this Study. The distance 











































Figure 2.7: Markers in the PKD2 Region on Chromosome 4q2 l-22 Used in this Study. The distance 
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Figure 2.8: Markers in the PKDL Region on Chromosome I Oq24 Used in this Study. The distance 
between genetic markers are indicated in centimorgans (cM). The distance between the genetic marker 
DIOS 185 and PKDL is 7.9cM. 
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Figure 3.1: Age Distribution in the Three ADPKD Populations. A -
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Figure 3.2: Survival Analysis to CRF (observed age) between the Three 
Countries. No significant difference in renal survival to CRF ( observed 
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Figure 3.3:Censored Survival Analysis to CRF (observed and extrapolated 
age) between the Three Countries. No significant difference in renal survival 
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Figure 3.4: Survival Analysis to ESRF in Patients with ESRF between the 
Three Countries. No significant difference in renal survival to ESRF in 
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Figure 3.5: Censored Survival Analysis to ESRF between the Three 
Countries in all Patients. No significant difference in renal survival to ESRF in 






























Figure 4.1: Survival Analysis to CRF in Definite PKO I and PKD2 Subjects. A 
marginal difference in renal survival to CRF between definite PKDI and PKD2 
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Figure 4.2: Survival Analysis to ESRF in Definite PKDI and PKD2 
Subjects. No significant difference in cumulative renal survival was found 















Figure 4.3: Survival Analysis to CRF in PKD I (definite plus probable) and 
PKD2 subjects. A marginal difference was found in renal survival to CRF 
between PKDJ (definite and probable) and PKD2 subjects (p=0.05) 
1.2,-------------, 




Figure 4.4: Survival Analysis to ESRF in PKD l (definite plus probable) and 
PKD2 Subjects. A marginal difference was found in renal survival to ESRF 
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Figure 5.1: The Renin-angiotensin System Pathway. 
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Figure 5.3: Plasma ACE Activity in ADPKD Individuals with 


































10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 
Age in years 



























0 20 40 60 80 
Age at CRF 
Figure 6.2: Cumulative Survival to CRF in ADPKD Patients According to 
Smoking Status. No significant difference in renal survival was found between 
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Figure 6.3: Cumulative Survival to CRF in ADPKD Patients Based on Smoking 
Duration. No significant difference in renal survival was found between smoking 
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Figure 6.4: Cumulative Survival to CRF in ADPKD Patients Based on 
Daily Number of Cigarettes. No significant difference in renal survival 
according to smoking number (p=0.08) 
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Figure 6.5: Cumulative Survival to ESRF in ADPKD Patients Based on 
Smoking Status. No significant difference in renal survival found 
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Figure 6.6: Cumulative Survival to ESRF According to Smoking Duration. 
No significant difference in renal survival according to smoking duration 
was found (p=0.38) 
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Figure 6.7: Cumulative Survival to ESRF in ADPKD Patients Ba ed on Daily 
Number of Cigarettes. No significant difference in renal survival according to 
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Figure 6.8: Cumulative Survival to CRF in ADPKD Patients According to 
Alcohol Consumption. No significant difference in renal survival between alcohol 
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Figure 6.9: Cumulative Survival to ESRF in ADPKD Patients According to 
Alcohol Consumption. No significant difference in renal survival between alcohol 
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Figure 6.10: Cumulative Survival to CRF Based on Cholesterol Levels. No 
significant difference in renal survival was found between cholesterol groups 
(p=0.86) 
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Figure 6.11: Cumulative Survival to ESRF Based on Cholesterol Levels. No 
significant difference in renal survival was found between cholesterol groups 
(p=0.06) 
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Figure 6.12: Cumulative Survival to CRF Based on Triglyceride Levels. 
No significant difference in renal survival was found between triglyceride 
groups (p=081) 
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Figure 6.13: Cumulative Survival to ESRF Based on Triglyceride Levels. 











































































































































































A Novel Member of the Polycystin Family 25971 
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Fro. 3. Expression of PKDL gene. The first 1.5 kb of coding sequence was used as a probe. A, RNA dot blot hybridization analysis. Dot Al, 
whole brain; A2, aroygdala; A3, caudate nucleus; A4, cerebellum; A5, cerebral cortex:; A6, frontal lobe; A 7, hippocampus; AB, medulla oblongata; 
BI, occipital lob ; 82, putamen; 83, substantia nigra; B4, temporal lobe; 85, thalamus; B6, subthalamic nucleus; B7, spinal cord; Cl, heart; C2, 
aorta; C3, skeletal muscle; C4, colon; C5, bladder; C6, uterus; 07, prostate; CB, stomach; DI , testis; D2, ovary; D3, pancreas; D4, pituitary gland; 
D5, adrenal gland; D6, thyroid gland; D7, salivary gland; DB, mammary gland; EI , kidney; E2, liver; E3, small intestine; E4, spleen; E5, t.hymus; 
E6, peripheral leukocyte; E7, lyI11ph node; EB, bone marrow; Fl , appendix; F2, lung; F3, trachea; F4, placenta; GI, fetal brain; G2, fetal heart; G3, 
fetal kidney; G4, fet.a.l liver; G5. fetal spleen ; 06, fetal thymus; 07, fetal lung; HJ , yeast total RNA 100 ng; H2 , yeast tRNA 100 ng; H3, Escherichia 
coli rRNA 100 ng; H4, E.coli DNA 100 ng; H5, poly(rA) 100 ng; H6, human Cot.-1 DNA 100 ng; H7, human DNA 100 ng; HB, human DNA 500 ng. 











Frc. 4. Chromosomal localization of the human PKDL gene. A, ideogram of human chromosome 10 showing the map location of human 
PKDL at 10q24 (arrow). B, photograph of human metaphase chromosome counterstained with 4,6-diamidino-2-pbenylindole dihydrochloride. The 
two chromosomes are indicated by numbers. Arrows point to the site of hybridization of the digoxigenin-labeledlmman PKDL on both chromosomes 
10 in band q24. 
sites with strong motif sequences in the C-tenninal cytoplasmic 
domain. Two other putative protein kinase C phosphorylation 
sites are also found in the N-terminal cytoplasmic domain. 
Phosphorylation of these motif sequences may be involved in 
the gating process of the channel. Another scenario is that the 
channel is gated by a direct or indirect signal from associating 
proteins, e.g. polycy tin-1. Given that polycystin-1 has domains 
that may be involved in cell-cell or cell-matrix interaction and 
is known to interact with polycystin-2 (7, 8), we hypothesize 
that the binding ofligand(s) to polycystin-1 may be associated 
with the gating of a polycystin-related channel. 
Sequence analysis and comparison to other channels support 
the six or seven membrane-spanning plus one pore-region to-
pology of polycystin-2 and polycystin-L. In addition to the five 
putative transmembrane segments, the middle of the three 
relatively hydrophobic peaks, which corresponds to 84 in al 
subunits of cation channels, is likely to be another transmem-
brane segment. Whether the N-terminal peak (Sl/2) forms a 
membrane-spanning region is not clear. 
One common feature of the polycystin-:Upolycystin-2 struc-
ture that is rarely observed in known ion channels is that they 
both have relatively long extracellular loops between the first 
25972 A Novel Member of the Polycystin Family 
TABL.E I 
Individual and cumulative lod scores from six families 
Family Bulga l is not informative for aU markers. 
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Fm. 5. A, man-mouse map of the PKDL 
locus. B, Southern blot analysis of Krd 
mice. Genomic DNA from t.be indicated 
strains was digested with Taqr, blotted, 
and probed with a 1.5 kb of human PKDL 
cDNA probe. The hybridizing fragments 
present in strains C57BL/6J and C3HI 
Hej are not inherited in the (Krd x 
SPRET) Fl mice, indicating that the 
mouse homologue of PKDL is deleted in 
Krdmice. 





10q24-25 CYP17 - - - Cyp17 46.0 
1.6 -
10q25-26 ADRA2A - - Adra2a 50.0 
and the second putative transmembrane segments. Although 
this loop region does not show high homology to any known ion 
channels, polycystin-2 and polycystin-L maintain a high level 
of homology with each other in this region. Moreover, this 
region contains a 13-amino acid stretch with 3 to 4 basic resi-
dues that is conserved not only between polycystin-2 and poly-
cystin-L but also with polycystin-1. The function of this poly-
cystin-shared motif is not clear. 
Chromosomal Assignment and Linkage Studies-Studies us-
ing D10S603, which maps to the same interval as PKDL by 
radiation hybrid mapping, and two adjacent markers, Dl0Sl92 
and D10S198, did not reveal linkage in six. non-PKDl, non-
PKD2 families, making it unlikely that mutations in PKDL 
cause the disease in these families. Among other as yet unex-
plained human cystic kidney diseases, it is unlikely that PKDL 
plays a role in autosomal recessive polycystic kidney disease, as 
mutations in most autosomal recessive polycystic kidney dis-
ease families have been mapped to chromosome 6 (32). The 
PKDL locus can, however, be considered as a candidate for 
unmapped human genetic cystic disorders such as dominantly 
transmitted glomerulocystic kidney disease of postinfantile on-
set (33), isolated polycystic liver disease (34), and Hajdu-
Cheney syndrome/serpentile fibula syndrome 35, 36). 
The region syn.tenic to the human PKDL locus is located on 
chromosome 19 in mice (26). This region is partially deleted in 
mice with the mutation Krd (Kidney and retinal defects) (27). 
The 7 centimorgans Krd deletion is located between Tdt and 
Cyp17 and includes the paired box gene Pax2. Mice heterozy-
gous for a null mutation of Pax2 frequently demonstrate reduc-
tion in kidney weight, which ranges from 10 to 100% normal 
(37). The reduced size is due mainly to calyceal and proximal 
ureteral diminution as well as cortical thinning, with a reduced 
number of developing nephrons (37). In contrast, the phenotype 
of Krd/ + heterozygotes includes aplastic, hypoplastic, and cys-
tic kidneys, as well as reduced viability on strain C57BL/6J 
(27). Our Southern analysis demonstrates that the mouse or-
tholog of PKDL is deleted in Krd mice. Further study is needed 
to clarify the contribution of Pkdl to theKrd phenotype. 
Several other congenital murine and rat models with poly-
cystic kidney disease are also known to exist, although the 
genetic defects in these models are as yet to be identified (38, 
39). Among mouse PKD models, loci for cpk, bpk, pcy, jck, jcpk, 
kd have been mapped to mouse chromosomes 12, 10, 9, 11, 10, 
and 10, respectively, and are unlikely to involve the mouse 

